Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06329401
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:01.897221+00:00
Published At
2026-04-06T00:00:00+00:00
Record Updated At
2026-04-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Pulmonary Fibrosis", "Progressive Pulmonary Fibrosis", "Pulmonary Fibrosis Secondary to Systemic Sclerosis", "Pulmonary Fibrosis, Interstitial Lung Disease", "Interstitial Lung Disease", "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)", "Interstitial Lung Disease in Patients With Rheumatoid Arthritis", "Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere", "Hypersensitivity Pneumonitis", "Interstitial Lung Disease With Systemic Sclerosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-06"
protocolSection.identificationModule.nctId
"NCT06329401"
protocolSection.identificationModule.officialTitle
"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Pulmonary Fibrosis (protocolSection.conditionsModule.conditions)
  • Progressive Pulmonary Fibrosis (protocolSection.conditionsModule.conditions)
  • Pulmonary Fibrosis Secondary to Systemic Sclerosis (protocolSection.conditionsModule.conditions)
  • Pulmonary Fibrosis, Interstitial Lung Disease (protocolSection.conditionsModule.conditions)
  • Interstitial Lung Disease (protocolSection.conditionsModule.conditions)
  • Interstitial Lung Disease Due to Connective Tissue Disease (Disorder) (protocolSection.conditionsModule.conditions)
  • Interstitial Lung Disease in Patients With Rheumatoid Arthritis (protocolSection.conditionsModule.conditions)
  • Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere (protocolSection.conditionsModule.conditions)
  • Hypersensitivity Pneumonitis (protocolSection.conditionsModule.conditions)
  • Interstitial Lung Disease With Systemic Sclerosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.